Western Pacific Wealth Management LP Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Western Pacific Wealth Management LP reduced its stake in Johnson & Johnson (NYSE:JNJ) by 33.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,515 shares of the company’s stock after selling 1,241 shares during the quarter. Western Pacific Wealth Management LP’s holdings in Johnson & Johnson were worth $364,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JNJ. Powers Advisory Group LLC grew its stake in Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after purchasing an additional 61 shares in the last quarter. Eagle Wealth Strategies LLC lifted its holdings in Johnson & Johnson by 2.8% during the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock worth $372,000 after buying an additional 63 shares during the last quarter. Knuff & Co LLC lifted its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after buying an additional 64 shares during the last quarter. Perkins Coie Trust Co lifted its holdings in Johnson & Johnson by 1.8% during the 3rd quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock worth $600,000 after buying an additional 65 shares during the last quarter. Finally, Vertex Planning Partners LLC lifted its holdings in Johnson & Johnson by 1.3% during the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after buying an additional 65 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.8 %

Shares of JNJ stock opened at $154.68 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market cap of $372.41 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. The business’s fifty day moving average is $147.51 and its 200-day moving average is $156.09. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm earned $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Ratings Changes

A number of research analysts have commented on JNJ shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Citigroup cut their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Insider Buying and Selling

In related news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.